Blood Clotting (Coagulation)

Definition of Blood Clotting (Coagulation):

• Blood clotting, or coagulation, is a complex physiological process that prevents excessive bleeding (hemostasis) when a blood vessel is injured.
• It involves platelets, clotting factors, and the coagulation cascade to form a stable fibrin clot.

Phases of Blood Clotting

1. Vascular Spasm (Vasoconstriction):

   • Immediate narrowing of the blood vessel to reduce blood flow.

2. Platelet Plug Formation (Primary Hemostasis):

   • Platelet Adhesion: Platelets stick to exposed collagen in damaged blood vessels.
   • Platelet Activation: Platelets release chemicals (ADP, thromboxane A2) to attract more platelets.
   • Platelet Aggregation: Platelets form a temporary plug.

3. Coagulation Cascade (Secondary Hemostasis):

   • Sequential activation of clotting factors leads to the formation of a fibrin mesh that stabilizes the platelet plug.

4. Clot Retraction and Repair:

   • The clot contracts to reduce size and facilitate tissue repair.

5. Clot Dissolution (Fibrinolysis):

   • Plasmin breaks down the clot once healing is complete.

Coagulation Pathways

1. Intrinsic Pathway (Contact Activation):

   • Activated by damage inside blood vessels.
   • Factors: XII → XI → IX → VIII → X.

2. Extrinsic Pathway (Tissue Factor Pathway):

   • Activated by external trauma releasing tissue factor (TF).
   • Factors: TF → VII → X.

3. Common Pathway:

   • Both pathways converge at Factor X, activating thrombin.
   • Thrombin converts fibrinogen into fibrin, forming the final clot.

Key Clotting Factors

• Factor I: Fibrinogen – Converted to fibrin.
• Factor II: Prothrombin – Converted to thrombin.
• Factor III: Tissue factor (TF) – Activates extrinsic pathway.
• Factor IV: Calcium – Essential cofactor in clotting.
• Factor VIII and IX: Deficiencies cause Hemophilia A and B.
• Factor XIII: Cross-links fibrin to stabilize the clot.

Disorders of Blood Clotting

1. Bleeding Disorders (Hypocoagulable States):

   • Hemophilia (A – Factor VIII, B – Factor IX deficiency).
   • Von Willebrand Disease: Defective platelet adhesion.
   • Thrombocytopenia: Low platelets.
   • Liver Disease: Impaired clotting factor synthesis.
   • Vitamin K Deficiency: Affects Factors II, VII, IX, X.

2. Excessive Clotting Disorders (Hypercoagulable States):

   • Deep Vein Thrombosis (DVT): Clots in deep veins.
   • Pulmonary Embolism (PE): Clot migration to lungs.
   • Disseminated Intravascular Coagulation (DIC): Widespread clotting followed by bleeding.
   • Thrombophilia: Genetic predisposition (e.g., Factor V Leiden).

Diagnosis

1. Coagulation Tests:

   • PT (Prothrombin Time): Extrinsic pathway, monitors warfarin.
   • INR: Standardized PT value.
   • aPTT (Activated Partial Thromboplastin Time): Intrinsic pathway, monitors heparin.
   • Thrombin Time (TT): Fibrinogen conversion assessment.

2. Platelet Tests:

   • Count and Bleeding Time: Platelet number and function.

3. Special Tests:

   • D-Dimer: Detects clot breakdown products (DVT, PE).
   • Fibrinogen Levels: Checks for deficiencies.
   • Factor Assays: Identifies specific deficiencies.

Treatment

1. Bleeding Disorders:

   • Replacement Therapy: Clotting factors (Factor VIII for Hemophilia A).
   • Desmopressin (DDAVP): Releases von Willebrand factor.
   • Vitamin K Supplementation: For deficiencies.
   • Platelet Transfusion: In thrombocytopenia.

2. Clotting Disorders (Hypercoagulability):

   • Anticoagulants:
     • Heparin: Immediate effect (intrinsic pathway).
     • Warfarin: Long-term use (extrinsic pathway).
     • DOACs: Apixaban, Rivaroxaban.
   • Thrombolytics (Fibrinolytics): Alteplase for DVT, PE, stroke.
   • Antiplatelets: Aspirin, Clopidogrel to prevent aggregation.
   • Compression Therapy: Prevents clotting in immobile patients.

Complications

• Bleeding: From anticoagulants or clotting factor deficiencies.
• Thromboembolism: Migrating clots causing PE, stroke.
• Organ Damage: Hypoperfusion due to clots.

Prognosis

• Early Treatment: Improves survival and outcomes.
• Chronic Conditions: Require long-term management.
• Advances in Therapy: Improved outcomes for high-risk patients.

Thank you for reading from Firsthope's notes, don't forget to check YouTube videos!